Core Laboratories (CLB) Cash & Equivalents (2022 - 2026)

Core Laboratories' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $22.8 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 3.22% year-over-year to $22.8 million in Q1 2026; TTM through Mar 2026 was $22.8 million, a 3.22% increase from a year earlier, with the FY2025 full-year figure at $22.7 million, up 18.5% from the prior year.
• Cash & Equivalents climbed to $22.8 million in Q1 2026 per CLB's latest filing, from $22.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $31.2 million in Q2 2025 and bottomed at $14.9 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $21.5 million (2024), against an average of $20.9 million.
• Across the five-year window, Cash & Equivalents tumbled 32.47% in 2024 and soared 76.25% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $15.4 million in 2022, then decreased by 2.0% to $15.1 million in 2023, then grew by 26.7% to $19.2 million in 2024, then climbed by 18.5% to $22.7 million in 2025, then grew by 0.52% to $22.8 million in 2026.
• Per Business Quant, the three latest CLB Cash & Equivalents figures stand at $22.8 million (Q1 2026), $22.7 million (Q4 2025), and $25.6 million (Q3 2025).